Warrants carry a $0.0001 exercise price in 4D Molecular Therapeutics (FDMT) ownership amendment.
BVF Partners L.P. and affiliated entities reported an amended passive investment disclosure (SCHEDULE 13G/A) for 4D Molecular Therapeutics (FDMT), indicating beneficial ownership of approximately 9.99% of the common stock as of September 30, 2026. The filing highlights that the reporting persons held Pre-Funded Warrants exercisable for 7,544,945 shares at an exercise price of $0.0001 per share, with an aggregate exercise limit of 2,932,571 shares due to a 9.99% blocker.
A new employee gets 21,800 stock awards at 4D Molecular Therapeutics
4D Molecular Therapeutics (FDMT) granted 21,800 restricted stock units (RSUs) to a new non-executive employee on November 10, 2026. These RSUs were issued under the company’s amended 2025 Employment Inducement Award Plan to attract new talent, as per Nasdaq Global Market Rule 5635(c)(4). The grants represent potential shareholder dilution but are a common equity compensation award used to incentivize new hires.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted 21,800 Restricted Stock Units (RSUs) to a new non-executive employee on November 10, 2026. These grants were made under the company's 2025 Employment Inducement Award Plan to attract new talent, in accordance with Nasdaq Global Market rules. 4DMT is a late-stage biotechnology company focused on developing therapies for diseases like wet age-related macular degeneration, diabetic macular edema, and cystic fibrosis.
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its Q3 2026 financial results, highlighting significant progress in its clinical programs for retinal diseases. Key achievements include completing enrollment for two pivotal Phase 3 trials of 4D-150 in wet AMD and initiating a global Phase 3 trial for 4D-150 in Diabetic Macular Edema (DME). The company maintains a strong cash position of $375 million, expected to fund operations into the second half of 2028.
4D Molecular Therapeutics, Inc. (FDMT) Misses Q3 EPS by 3c
4D Molecular Therapeutics, Inc. (FDMT) reported a Q3 EPS of ($1.08), missing analyst estimates by $0.03. However, the company's revenue for the quarter came in at $4.15 million, surpassing the consensus estimate of $3.46 million. The article provides financial details for investors interested in FDMT's performance.
Two late-stage trials of an eye treatment are expected to report results in 2027
4D Molecular Therapeutics reported its third-quarter 2026 financial results, with a widened net loss of $78.056 million and increased collaboration revenue of $4.145 million. The company completed randomization for its two pivotal wet age-related macular degeneration trials, 4FRONT-1 and 4FRONT-2, with topline data expected in Q2 2027 and H2 2027, respectively. Additionally, 4DMT initiated the 4SIGHT Phase 3 trial for diabetic macular edema and projects its existing funds and anticipated Otsuka payments to support operations into the second half of 2028.
FDMT: Fully enrolled Phase III trials put 4D-150 on track for 2027 wet AMD readouts
4D Molecular Therapeutics, Inc. (FDMT) has fully enrolled its Phase III trials for 4D-150, an investigational treatment for wet age-related macular degeneration (AMD). The drug aims to provide continuous disease control with a single intravitreal dose, with topline results anticipated in Q2 and H2 2027. Earlier Phase II data indicated reduced treatment burden and maintained vision in newly diagnosed patients.
Shared voting rights cover 2.42M shares in State Street's 4D Molecular Therapeutics (FDMT) stake.
State Street Corporation has disclosed its beneficial ownership in 4D Molecular Therapeutics, Inc. (FDMT), holding 2,469,425 shares, which represents 4.5% of the class as of September 30, 2026. The filing indicates that State Street reported shared voting power over 2,416,070 shares and shared dispositive power over 2,469,425 shares. This information was reported via an SEC Schedule 13G filing.
Seven conference talks are scheduled for 4DMT. Recordings will stay online for up to a year.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its management will participate in and present at seven investor conferences throughout November and December 2026. The appearances will feature one-on-one meetings and fireside chats, with webcasts of the presentations available on the company's investor relations website for up to one year. This engagement aims to provide updates on 4DMT's late-stage biotechnology programs, including its lead product candidates 4D-150 and 4D-710.
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics (FDMT) is developing 4D-150, an investigational gene therapy for wet age-related macular degeneration (wet AMD), designed to reduce the need for frequent anti-VEGF injections. Phase IIb PRISM study data showed a significant reduction in treatment burden with stable visual acuity and retinal anatomy. The company has fully enrolled two Phase III studies (4FRONT-1 and 4FRONT-2) and anticipates results in the first and second half of 2027, respectively, aiming for non-inferiority against aflibercept.
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics (FDMT) is developing 4D-150, an investigational gene therapy for wet age-related macular degeneration (wet AMD), aiming to reduce the burden of frequent anti-VEGF injections. The therapy, administered as a single intravitreal injection, is designed to provide continuous disease control. Positive Phase IIb PRISM study data showed a significant reduction in the need for supplemental injections, and two Phase III studies are fully enrolled, with results expected in 2027.
4D Molecular Therapeutics, Inc. Estimates – NASDAQ:FDMT
This page provides an overview of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) financial estimates and actuals, allowing users to explore reported financial data and analyst estimates. It covers the income statement, balance sheet, cash flow statement, and various valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for both annual and quarterly data.
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $33
BofA Securities has reiterated its Buy rating on 4D Molecular Therapeutics (FDMT.US), keeping the target price at $33. This indicates a continued positive outlook from the firm regarding the company's stock performance.
H.C. Wainwright reiterates 4D Molecular stock rating at buy
H.C. Wainwright has reiterated a Buy rating and a $36.00 price target for 4D Molecular Therapeutics (NASDAQ:FDMT), aligning with a broader "Strong Buy" analyst consensus. The firm's positive outlook follows an R&D Investor Day where discussions highlighted the potential of 4D-150 gene therapy for chronic wet AMD treatment. The company maintains a strong financial position, and its stock is considered undervalued despite high volatility, with pivotal Phase 3 trial results anticipated in 2027.
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics (FDMT) is developing 4D-150, a potential one-time intravitreal gene therapy for wet age-related macular degeneration (wet AMD), aimed at reducing the burden of frequent anti-VEGF injections. Phase IIb PRISM study data showed a significant reduction in treatment burden, with nearly half of treated eyes requiring no supplemental injections over two years. The company has fully enrolled two Phase III studies (4FRONT-1 and 4FRONT-2) and anticipates results in 2027, with a commercial strategy focused on in-office administration and Medicare Part B reimbursement.
4D Molecular Therapeutics Rings the Nasdaq Stock Market Closing Bell
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, visited the Nasdaq MarketSite in Times Square for a bell ceremony. David Kirn, M.D., Co-founder, President, and CEO, rang the Closing Bell to commemorate the occasion. This event is part of Nasdaq's regular market opening and closing ceremonies held in Times Square and globally.
Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock By Investing.com
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold 1,635 shares of the company's common stock for $20,993 on October 16, 2026, while concurrently acquiring the same number of shares for $6,768. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted in January 2026. Following these sales, Bizily holds 8,617 shares directly and 56,431 stock options, as the company's stock shows high volatility despite being considered undervalued by InvestingPro analysis.
FDMT: 4D-150 targets continuous wet AMD control, with two pivotal readouts expected in 2027
4D Molecular Therapeutics' (FDMT) 4D-150 aims to revolutionize wet AMD treatment by providing continuous control with fewer injections. Two fully enrolled Phase III trials are anticipated to release readouts in 2027. The company's commercial strategy focuses on in-office delivery and a phased adoption approach.
Form 4 4D Molecular Therapeutics Inc: Scott Bizily (CLO) For: 16 October
This article reports on a Form 4 filing for 4D Molecular Therapeutics Inc., detailing insider transactions by Scott Bizily, the company's Chief Legal Officer. The filing pertains to activities that occurred on October 16th. The report also notes a slight increase in the company's stock symbol, FDMT.
Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock
Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics (NASDAQ:FDMT), sold 1,635 shares of company stock for $20,993 on October 16, 2026, while simultaneously acquiring the same number of shares for $6,768. These transactions were executed under a pre-arranged trading plan. The article also notes that the stock is up significantly year-to-date, though still considered undervalued by InvestingPro, and highlights recent positive analyst updates and trial developments for the company.
After exercising options, legal chief sells 1,635 shares of 4D Molecular Therapeutics (FDMT).
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), exercised options for 1,635 shares at $4.14 per share and subsequently sold them at $12.84 per share on October 16, 2026. These transactions, made under a Rule 10b5-1 trading plan, resulted in an approximate pre-tax spread of $14,000. Bizily's post-transaction option position stands at 56,431 shares.
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced employment inducement grants to 13 new non-executive employees in September 2026. These grants, totaling 18,370 shares of common stock, were approved by the Compensation Committee and issued outside of the 2020 Incentive Award Plan. They are intended to comply with NASDAQ Listing Rule 5635(c)(4).
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (4DMT) announced that its compensation committee granted stock options for 260,000 shares and 157,600 Restricted Stock Units (RSUs) to 13 new non-executive employees. These grants were made on October 13, 2026, with an exercise price of $12.36 per share, under the company's 2025 Employment Inducement Award Plan to attract new talent. 4DMT is a late-stage biotechnology company focused on developing therapies for retinal vascular diseases and cystic fibrosis.
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)
This article highlights analyst ratings for three healthcare companies: 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). Barclays maintained a Buy rating for FDMT with a $28 price target, while Wells Fargo maintained a Hold rating for Pfizer with a $28 price target and for Incyte with a $128 price target. The article details the consensus ratings and average price targets from other analysts for each company.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)
Chardan Capital and Morgan Stanley analysts have issued bullish ratings for 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX), respectively. 4D Molecular Therapeutics received a "Buy" rating with a $25 price target, while Viking Therapeutics also received a "Buy" rating with a $95 price target. Both companies are in the Healthcare sector and are seen as strong buys by analyst consensus.
4D molecular therapeutics CEO David Kirn sells $753k in company stock
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold company stock worth over $753,000 on October 5, 2026, through a pre-arranged trading plan. Despite a recent dip, the stock is up 68% year-to-date and is considered undervalued by InvestingPro. Analysts have maintained positive ratings and increased price targets for FDMT due to promising trial data and advancements in its gene therapy programs.
Chardan Capital Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $25
Chardan Capital has initiated coverage on 4D Molecular Therapeutics (FDMT.US) with a Buy rating. The firm has set a target price of $25 for the company's stock.
4D molecular therapeutics CEO David Kirn sells $753k in company stock
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold company stock worth $753,937 on October 5, 2026, through a pre-arranged 10b5-1 trading plan. Despite the stock being down about 9% in the past week, it remains up 68% year-to-date, with InvestingPro analysis suggesting it is undervalued. Analysts have maintained positive ratings and increased price targets for FDMT, citing promising clinical trial data.
4D Molecular Therapeutics Insider Sold Shares Worth $753,937, According to a Recent SEC Filing
David Kirn, the Director, President, and CEO of 4D Molecular Therapeutics (FDMT), sold 58,333 shares of the company's stock on October 5, 2026. This transaction amounted to $753,937. The information is based on a recent SEC filing.
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com
This article announces the filing of Form 4 by 4D Molecular Therapeutics Inc for October 7. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by corporate insiders. The article briefly mentions the company's stock symbol FDMT and its recent performance.
Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com
This article reports on a Form 4 filing for 4D Molecular Therapeutics Inc. (FDMT) dated October 7th, as published by Investing.com. It is a brief announcement indicating a regulatory filing has been made for the company. The content primarily consists of market data and news unrelated to the main topic.
4D molecular therapeutics CEO David Kirn sells $753k in company stock
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ: FDMT), sold $753,937 worth of company stock on October 5, 2026, through a pre-arranged 10b5-1 trading plan. The sales involved 58,061 shares at an average of $12.9215 and 272 shares at $13.6104. Despite a recent dip, the stock is up 68% year-to-date and analysts maintain a positive outlook, citing promising trial data and de-risked studies.
4D Molecular Therapeutics, Inc. (FDMT) options chain – Yahoo Finance
This Yahoo Finance page provides the options chain for 4D Molecular Therapeutics, Inc. (FDMT), displaying detailed call and put option data for contracts expiring on January 15, 2027. It lists various strike prices, last trade dates, last prices, bid/ask, change, percentage change, volume, open interest, and implied volatility for each option. The page also shows current stock performance for FDMT and major global market indices.
CEO David Kirn sells 58,061 and 272 shares of 4D Molecular Therapeutics (FDMT) under a trading plan.
David Kirn, President and CEO of 4D Molecular Therapeutics (FDMT), reported selling a total of 58,333 shares of common stock on October 5, 2026. These sales, executed under a Rule 10b5-1 trading plan established on January 9, 2026, involved two separate transactions at weighted average prices of $12.9215 and $13.6104 per share. Following these transactions, Kirn directly holds 709,153 shares of the company's common stock.
Form 144 4D Molecular Therapeutics For: 5 October By Investing.com
This article from Investing.com reports on a Form 144 filing for 4D Molecular Therapeutics (FDMT) on October 5th. The filing indicates a recent transaction, with the stock currently down 5.49%. The piece is brief and does not offer additional details regarding the nature of the Form 144.
Officer David Kirn plans to sell 58,333 shares of 4D Molecular Therapeutics (FDMT).
David Kirn, an officer at 4D Molecular Therapeutics (FDMT), plans to sell 58,333 shares of Class A common stock valued at approximately $753,662.36. This sale is part of a pre-arranged selling plan dated January 9, 2026, designed to comply with Rule 10b5-1(c). The approximate sale date is October 5, 2026, with Goldman Sachs & Co. LLC acting as the broker.
4D Molecular Therapeutics Officer David Kirn Files Form 144 for Sale of 58,333 Shares
David Kirn, an officer at 4D Molecular Therapeutics, Inc., has filed a Form 144 for the proposed sale of 58,333 Class A Common shares, valued at over $753,000. This transaction is being conducted under a Rule 10b5-1(c) selling plan established on January 9, 2026, and will be facilitated by Goldman Sachs & Co. LLC. Kirn has made seven previous sales of the company's shares between July and September 2026, generating more than $3 million in gross proceeds.
Four retinal specialists will join company leaders in New York to discuss retinal disease treatment.
4D Molecular Therapeutics (FDMT) will host an Investor Day in New York City on October 21, 2026, starting at 10:30 AM ET. The event will focus on the clinical profile and commercial vision for their lead product candidate, 4D-150, which is designed to treat VEGF-driven retinal diseases. Renowned retinal experts will join company leadership to discuss transforming the treatment paradigm for these conditions.
4DMT to Host Investor Day on October 21, 2026
4D Molecular Therapeutics (4DMT) will host an Investor Day in New York City on October 21, 2026, at 10:30 am ET. The event will feature company presentations, KOL panel discussions, and a Q&A session, focusing on the clinical profile and commercial vision for 4D-150, a lead product candidate for retinal vascular diseases. Renowned retinal experts will join 4DMT leadership to discuss transforming treatment paradigms for VEGF-driven retinal diseases.
4DMT to Host Investor Day on October 21, 2026
4D Molecular Therapeutics (4DMT) will host an Investor Day on October 21, 2026, in New York City to provide insights into its lead product candidate, 4D-150, for VEGF-driven retinal diseases. The event will feature presentations from 4DMT leadership and renowned retinal experts, focusing on the clinical profile and commercial vision for transforming treatment paradigms. This will include discussions on 4D-150, currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema, and 4D-710 for cystic fibrosis.
B.Riley reiterates Buy on 4D Molecular stock, cites trial design
B.Riley has reiterated a Buy rating and a $37.00 price target for 4D Molecular Therapeutics (NASDAQ:FDMT), following a non-deal roadshow. The firm highlighted investor interest in the 4FRONT-1 trial readout, the impact of Kodiak Sciences' DAYBREAK results on gene therapy expectations, and the future adoption of 4D-150 for wet AMD and DME. Despite a smaller market cap compared to Kodiak, 4D Molecular is viewed as undervalued with strong financial health, including $431 million in cash funding operations past key trial readouts.
Insiders At 4D Molecular Therapeutics Sold US$757k In Stock, Alluding To Potential Weakness
This article analyzes recent insider selling at 4D Molecular Therapeutics, where insiders sold US$757k worth of stock over the last year. While this isn't necessarily a strong bearish signal on its own, it suggests that insiders might view the stock as fully valued given the lack of significant insider buying during the same period. The analysis encourages investors to consider multiple factors beyond just insider transactions when evaluating the company.
4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy
Over the past year, insiders at 4D Molecular Therapeutics (NASDAQ:FDMT) have sold US$757k worth of shares, primarily led by Co-Founder David Kirn. The sales, particularly one at US$12.87 per share (below the current US$14.49), suggest potential hesitancy from insiders, although selling can have various motivations. Despite the selling, insiders still own 2.8% of the company, valued at approximately US$23 million, which indicates some alignment with shareholder interests.
FDMT Maintains by B of A Securities -- Price Target Raised to $3
B of A Securities maintained its rating for 4D Molecular Therapeutics (FDMT) and raised its price target to $33.00, indicating optimism about the company's prospects. Despite being 55.6% undervalued according to GF Value, FDMT shows moderate overall performance with weaknesses in profitability and growth, and has recently experienced significant insider selling.
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
4D Molecular Therapeutics (FDMT) is reaffirmed as a 'Buy' due to the progress of its gene therapy, 4D-150, in phase 3 trials for wet AMD and diabetic macular edema (DME). The company anticipates topline data for its wet AMD studies in Q2 and H2 2027, with previous data indicating a significant reduction in injection burden for both conditions. 4D Molecular is financially stable through 2028 and has several upcoming catalysts, including updates on its cystic fibrosis program.
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics has advanced its 4D-150 treatment into Phase 3 development for diabetic macular edema (DME), marking its second large market retina indication. The company announced the enrollment of the first patients in the 4SIGHT global Phase 3 trial and presented updated 2-year data from the SPECTRA Part 1 trial, showing a favorable safety profile, durable vision and anatomic improvements, and significant treatment burden reduction. This move aims to establish 4D-150 as a continuous backbone therapy for VEGF-driven retinal diseases, potentially transforming DME treatment with a single intravitreal injection.
4D Molecular Therapeutics Begins Phase 3 4D-150 DME Trial
4D Molecular Therapeutics has initiated its global 4SIGHT Phase 3 trial for 4D-150 to treat diabetic macular edema, enrolling the first patients. The trial aims to demonstrate non-inferior vision outcomes with fewer aflibercept injections. Concurrently, two-year SPECTRA data showed 4D-150 was well tolerated, improved vision, reduced retinal thickness, and significantly cut projected injection burden by 61% to 75%.
A 9-person study reported 61% lower injection burden with 4D-150 versus a 13-shot projection.
4D Molecular Therapeutics (FDMT) has initiated its 514-patient 4SIGHT Phase 3 trial for 4D-150 in diabetic macular edema (DME), following positive two-year results from the earlier SPECTRA trial. In the SPECTRA trial, a nine-patient group receiving the Phase 3 dose of 4D-150 experienced a 61% reduction in supplemental injections compared to projected aflibercept injections. The company also announced alignment with the FDA and EMA for potential regulatory filings using a single DME Phase 3 trial, combined with data from other trials.
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics (4DMT) has initiated the 4SIGHT Phase 3 clinical trial for its product candidate 4D-150 in patients with diabetic macular edema (DME), marking its second Phase 3 program for a major retinal disease. The company reported positive 2-year data from the SPECTRA Part 1 trial, showing 4D-150 was well-tolerated with durable vision and anatomic improvements, and a significant reduction in treatment burden for DME patients. 4D-150, which uses an AAV vector to deliver anti-VEGF biologics, aims to provide long-lasting treatment with a single intravitreal injection, potentially transforming care for wet AMD and DME.
4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edema
4D Molecular Therapeutics has begun patient enrollment for its Phase 3 4SIGHT clinical trial, evaluating 4D-150 for diabetic macular edema (DME). The company also released positive two-year data from the SPECTRA clinical trial, showing a favorable safety profile and significant reduction in treatment burden for 4D-150. This development marks a key step towards regulatory submissions, with FDA RMAT designation already granted for 4D-150 in DME.